Uterine Serous Carcinoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The majority of endometrial cancer-related deaths are caused by uterine serous carcinoma, a relatively uncommon disease that accounts for 10% of all endometrial cancer diagnoses. Despite having a worse prognosis than patients with other endometrial cancer subtypes and a higher risk of recurrence, patients with serous endometrial cancer are frequently detected early in the disease's progression. Per 100,000 women, there are 27.8 new cases of uterine cancer annually. The annual death rate is 51 per 100,000 females. Based on cases from 2015 to 2019 and deaths from 2016 to 2020, these statistics have been adjusted for age. Treatment for endometrial cancer needs to be tailored to the patient's needs and the disease's stage. Although the majority of endometrial cancers and uterine sarcomas are treated surgically and through pathologic surgical staging, nonsurgical approaches like radiation therapy, chemotherapy, and hormone therapy are also important in the management of uterine cancer.

Description

Despite being relatively uncommon- Uterine Serous Carcinoma accounts for only about 10% of endometrial cancer diagnoses-uterine serous carcinoma is the cause of 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are frequently detected early in the disease's progression, but they have a worse prognosis than patients with other endometrial cancer subtypes due to a higher risk of recurrence. Marked karyotype loss and abnormal immunohistochemical p53 staining are two characteristics of serous endometrial carcinoma. Surgery, chemotherapy, and/or radiation therapy make up the mainstay of the primary treatment for newly discovered serous endometrial cancer. Unfortunately, poor survival rates persist despite these efforts. All endometrial cancers have recently been divided into four categories by the Cancer Genome Atlas (TCGA) research network, with serous endometrial cancers typically falling under the "high copy number" category. Cell cycle dysregulation was more common in this group, as evidenced by the high percentage of TP53 mutations (90%) and genes like CCNE1, MYC, PPP2R1A, PIKCA, ERBB2, and CDKN2A. With a 50% response rate in advanced/recurrent serous endometrial cancer, pembrolizumab and lenvatinib together have proven to be a successful second-line therapy. Given the unfavourable outcomes in serous endometrial cancer, clinical trials were regarded as a top priority. Approximately 15% of all female cancers are invasive tumors of the female pelvic organs. Uterine cancer is the most typical of these malignancies. Postmenopausal bleeding (PMB) is the most prevalent symptom in 90% of women. Although only 10-20% of postmenopausal women with vaginal bleeding have gynaecological cancers, most women are aware that an urgent investigation is necessary. 70-75% of women are identified as having stage 1 surgical disease following this quick assessment.

Uterine Serous Carcinoma (Epidemiology)

Every year, for every 100,000 women, there are 27.8 new cases of uterine cancer. Five and one deaths per 100,000 females occur annually. These numbers are based on deaths from 2016 to 2020 and cases from 2016 to 2019 that have been adjusted for age. Approximately 31% of women will receive a uterine cancer diagnosis at some point in their lives, according to data from 2017 to 2019. Uterine cancer affected 822,388 women in the US in 2019, according to statistics. Women of reproductive age and postmenopausal women can develop endometrial cancer, but postmenopausal women account for 75% of cases, with an average age at diagnosis of 61 years. Women who are perimenopausal who have specific risk factors are at high risk. Obesity, physical inactivity, irregular menstrual cycles, diabetes, high blood pressure, and irregular menstrual cycles are linked to the most prevalent low-grade endometrial cancers. Furthermore, the risk of primary ovarian cancer was 19-25% higher in these younger women.

Uterine Serous Carcinoma -Current Market Size & Forecast Trends

The market for uterine serous carcinoma is part of the broader uterine cancer landscape, which is expected to grow significantly. The global uterine cancer therapeutics and diagnostics market was valued at approximately USD 22.55 billion in 2023 and is projected to reach around USD 23.95 billion in 2024, with a compound annual growth rate (CAGR) of 6.29% through 2030. Specifically, the market for uterine serous carcinoma is anticipated to expand due to increasing awareness, advancements in treatment options, and ongoing research into targeted therapies and immunotherapies. Overall, the uterine serous carcinoma market is well-positioned for growth through 2035, as new therapeutic options and diagnostic technologies continue to emerge.

Depending on the patient's circumstances and the stage of the disease, endometrial cancer treatment should be customized. Although surgical treatment and pathologic surgical staging are the main treatments for the majority of endometrial cancers and uterine sarcomas, nonsurgical treatments like radiation therapy, chemotherapy, and hormone therapy are important in the management of uterine cancer. However, the majority of these therapies are applied as adjuvant therapy or in cases of metastatic or recurrent disease. The primary course of treatment for the majority of patients is surgical resection and staging. Abdominal exploration, pelvic lavage, a total hysterectomy, bilateral salpingo-oophorectomy, a biopsy of any suspicious lesions, and a pelvic/para-aortic lymphadenectomy were all included in the surgical staging. For complete staging, an omental biopsy is also necessary if serous or papillary carcinoma is present. Another instance of stage III disease where primary surgery is unlikely to completely remove the tumor is parameter-based stage III disease. Hysterectomy and appendectomy procedures are carried out, if at all possible, six weeks after the end of radiation treatment, even in this situation. Depending on the location of the disease, clinical stage IV disease is treated differently. Radiation therapy is frequently utilized for the local control of tumors when the tumor has spread to the bladder or rectum, as well as for the treatment of symptomatic bone and central nervous system metastases in addition to surgery to control bleeding. A lot of hormone therapy and chemotherapy might be necessary for advanced disease. Patients who are medically unable to undergo surgery typically cannot receive initial radiation therapy for uterine sarcoma.

Report Highlights

Uterine Serous Carcinoma - Current Market Trends

Uterine Serous Carcinoma - Current & Forecasted Cases across the G8 Countries

Uterine Serous Carcinoma - Market Opportunities and Sales Potential for Agents

Uterine Serous Carcinoma - Patient-based Market Forecast to 2035

Uterine Serous Carcinoma - Untapped Business Opportunities

Uterine Serous Carcinoma - Product Positioning Vis-a-vis Competitors' Products

Uterine Serous Carcinoma - KOLs Insight